Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Ohba, A; Morizane, C; Kawamoto, Y; Komatsu, Y; Ueno, M; Kobayashi, S; Ikeda, M; Sasaki, M; Furuse, J; Okano, N; Hiraoka, N; Yoshida, H; Kuchiba, A; Sadachi, R; Nakamura, K; Matsui, N; Nakamura, Y; Okamoto, W; Yoshino, T; Okusaka, T

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务